Monte Rosa Therapeutics(GLUE)

BOSTON, MABiotechnology1 H-1B visas (FY2023)

Focus: Monte Rosa is a Boston-based public biotech founded in 2024 specializing in small molecule cancer drugs that modulate protein degradation pathways (PROTAC technology). The company is early-stage with three clinical programs and recently completed a public offering (ticker: GLUE).

Oncology

Profile data last refreshed 2h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

19-3 this month

Stable — net -3 jobs in 30d

7 added, 10 removed. Backfill posture.

Should You Work at Monte Rosa Therapeutics?

AI assessment

Ideal for scientists and clinicians seeking high-risk/high-reward opportunity in emerging technology with near-term upside; less suitable for those prioritizing stability, mentorship depth, or near-term career acceleration.

Why Work Here

Platform technology with high R&D intensity (161%) signals deep investment in science and differentiation — you'll work on cutting-edge protein degradation mechanisms

Data completeness

3/9 — Basic

Company HealthStrong

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$76M

Pipeline & Clinical Trials

MRT-6160

Healthy Volunteers

PHASE_1

Clinical Trials (1)

NCT06597799First-in-human Study of MRT-6160 in Healthy Subjects

Phase 1

Help build intelligence for Monte Rosa Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Newly public company (2024) with $224M cash and growing revenue ($76M in FY2025) provides runway and expansion opportunity rare for early-stage biotech

Oncology focus in high-value therapeutic area with multiple Phase 1/1b programs creating early-career visibility and publication potential

Watch Out For

Pre-revenue commercial status with only 3 clinical trials total and no Phase 3 programs means 3-5+ year timeline to major value inflection — significant execution risk
Heavy R&D burn ($122M in FY2025) against modest revenue creates pressure; company swung from -$135M to -$73M net loss YoY, requiring sustained capital discipline
Only 22 active job openings and recent founding suggests limited internal mobility and mentorship depth compared to established biotech

Generated by Claude from Monte Rosa Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

MRT-8102

Healthy Volunteers

PHASE_1

Clinical Trials (1)

NCT07119125A First-in-human, 3-part Study of MRT-8102 in Healthy Participants and Participants at Cardiovascular Risk With Elevated CRP

Phase 1

Oral MRT-2359

NSCLC

PHASE_1_2

Clinical Trials (1)

NCT05546268Study of Oral MRT-2359 in Selected Cancer Patients

Phase 1/2

Interview Prep Quick Facts

Founded: 2024

Portfolio: 3 clinical trials

Top TAs: Oncology

H-1B (2023): 1 approval

SEC Filings: 2 available

Open Roles: 19 active jobs

Therapeutic Area Focus

Oncology

1 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$76M

R&D Spend

$122M(161%)9%

Net Income

-$73M

Cash

Hiring Trend

Slowing Down

Open Roles

Added

-3

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Monte Rosa Therapeutics(GLUE)

Should You Work at Monte Rosa Therapeutics?

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Open Jobs (19)

Development Operations Coordinator, CMC/DMPK (Contractor)

Scientist I/II Analytical CMC & QC

Intern – Cell Biology (6 Month Contract)

Contractor High Throughput Cellular Assays (6 Months)

Director, Program Management I & I Full Life Cycle

Manager, Regulatory Operations

Research Associate Proteomics

Manager – Quality GCP

Director, Clinical Science

Manager, Regulatory Affairs Associate

Research Associate, Automation & Screening (6 Month Contract)

Intern, Synthetic Chemistry (6 Months)

Senior Scientist, Medicinal Chemistry Discovery

Director, Regulatory Affairs – Global Regulatory Strategy

Director, Financial Planning & Analysis

Director / Associate Director – Toxicology

Director, Drug Safety & Pharmacovigilance (Inflammation & Oncology)

Director, Biostatistics

Associate Director, CMC - Contracts Management

Financials (FY2025)

Hiring Trend

Visa Sponsorship